{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:32:33Z","timestamp":1792531953695,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Suvorexant, lemborexant, and daridorexant are dual orexin receptor antagonists (DORAs) used to treat insomnia, offering a lower abuse potential due to their lack of gamma-aminobutyric acid activity compared to traditional sleep medications. Still, DORAs remain drugs of forensic interest due to their accessibility, long half-lives, and potential risk for next-day residual drowsiness, impaired motor coordination, and decreased alertness, which may feature prominently in cases of driving impairment or drug-facilitated sexual assault. Thus, developing analytical methods to detect these compounds, particularly the more novel lemborexant and daridorexant, is crucial for forensic toxicological testing. This study aimed to develop and validate an LC-MS\/MS method for quantifying daridorexant, lemborexant, and suvorexant in blood. An acidic\/neutral liquid\u2013liquid extraction (LLE) using N-butyl chloride was optimized to isolate the three DORAs and the internal standard, suvorexant-d6, from bovine blood. All accuracy, precision, and key validation parameters met acceptability requirements per ANSI\/ASB 036. LLE recovery was &amp;gt;94%, with the calibration range between 0.25 and 500\u2009ng\/mL for all analytes. The LLOQ was 0.25\u2009ng\/mL. Matrix effects were \u221254.2 to 75.7%. Bias ranged between \u221210.9% and 8.8%, while %CV was &amp;lt;17.7%. Two-fold dilution integrity studies yielded a bias &amp;lt;\u22127.6%, with %CV &amp;lt;7.6%. Exogenous\/endogenous interferences were negligible. Re-injection of the blank following the highest calibrator was free from carryover. Extracts were stable beyond 48\u2009h when stored at 4\u00b0C. A proof-of-concept study using authentic blood samples containing suvorexant, compared to previously reported concentrations, showed no consistent decrease over time, highlighting the need for further studies to determine optimal storage conditions for long-term stability. Although further studies are needed with authentic samples containing lemborexant or daridorexant, this validated method supports broader adoption in forensic toxicology, enhancing the detection and monitoring of these emerging sedative-hypnotics in forensic investigations.<\/jats:p>","DOI":"10.1093\/jat\/bkaf032","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T07:45:39Z","timestamp":1745307939000},"page":"469-475","source":"Crossref","is-referenced-by-count":4,"title":["Quantification of daridorexant, lemborexant, and suvorexant in whole blood using liquid chromatography\u2013tandem mass spectrometry"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8873-8993","authenticated-orcid":false,"given":"Munchelou M","family":"Gomonit","sequence":"first","affiliation":[{"name":"Department of Forensic Science, College of Criminal Justice, Sam Houston State University , Huntsville, TX 77340,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0142-2286","authenticated-orcid":false,"given":"Britni N","family":"Skillman","sequence":"additional","affiliation":[{"name":"Department of Forensic Science, College of Criminal Justice, Sam Houston State University , Huntsville, TX 77340,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"2025122016065355700_R1","article-title":"Chronic insomnia. In StatPearls. StatPearls Publishing, Treasure Island (FL)","author":"Kaur","year":"2024"},{"key":"2025122016065355700_R2","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.5665\/SLEEP.1230","article-title":"Insomnia and the performance of US workers: results from the America Insomnia Survey","volume":"34","author":"Kessler","year":"2011","journal-title":"Sleep"},{"key":"2025122016065355700_R3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1207\/S15402010BSM0104_5","article-title":"Insomnia as a health risk factor","volume":"1","author":"Taylor","year":"2003","journal-title":"Behav Sleep Med"},{"key":"2025122016065355700_R4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/2045125317753340","article-title":"Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation","volume":"8","author":"Fluyau","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"key":"2025122016065355700_R5","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.5664\/jcsm.7282","article-title":"An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics","volume":"14","author":"Janto","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"key":"2025122016065355700_R6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/cpdd.817","article-title":"Pharmacokinetics, pharmacodynamics, and safety of the dual orexin receptor antagonist lemborexant: findings from single-dose and multiple-ascending-dose phase 1 studies in healthy adults","volume":"10","author":"Landry","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2025122016065355700_R7","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.5665\/sleep.5168","article-title":"On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers","volume":"38","author":"Vermeeren","year":"2015","journal-title":"Sleep"},{"key":"2025122016065355700_R8","volume-title":"Suvorexant (Belsomra)","author":"Food and Drug Administration","year":"2014"},{"key":"2025122016065355700_R9","volume-title":"Lemborexant (Dayvigo)","author":"Food and Drug Administration","year":"2023"},{"key":"2025122016065355700_R10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","article-title":"Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders","volume":"16","author":"Muehlan","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025122016065355700_R11","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsy260","article-title":"On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers","volume":"42","author":"Vermeeren","year":"2018","journal-title":"Sleep"},{"key":"2025122016065355700_R12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5664\/jcsm.8294","article-title":"Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening","volume":"16","author":"Murphy","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"2025122016065355700_R13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.sleep.2024.07.019","article-title":"Dose-response of daridorexant in insomnia disorder: an analysis of Phase 2 and 3 studies","volume":"121","author":"Luyet","year":"2024","journal-title":"Sleep Med"},{"key":"2025122016065355700_R14","volume-title":"Daridorexant (Quviviq)","author":"Food And Drug Administration","year":"2022"},{"key":"2025122016065355700_R15","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s00228-022-03381-4","article-title":"Daridorexant for the treatment of insomnia disorder: findings and implications","volume":"78","author":"Dos Santos","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"2025122016065355700_R16","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/1440-1681.13370","article-title":"The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin","volume":"47","author":"Zenklusen","year":"2020","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2025122016065355700_R17","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab224","article-title":"Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem","volume":"45","author":"Ufer","year":"2022","journal-title":"Sleep"},{"key":"2025122016065355700_R18","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cpt.2592","article-title":"Driving performance after bedtime administration of daridorexant, assessed in a sensitive simulator","volume":"111","author":"Muehlan","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2025122016065355700_R19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jchromb.2015.07.056","article-title":"Determination of suvorexant in human plasma using 96-well liquid\u2013liquid extraction and HPLC with tandem mass spectrometric detection","volume":"1002","author":"Breidinger","year":"2015","journal-title":"J Chromatogr B"},{"key":"2025122016065355700_R20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jchromb.2016.10.042","article-title":"Quantification of suvorexant in urine using gas chromatography\/mass spectrometry","volume":"1040","author":"Carson","year":"2017","journal-title":"J Chromatogr B"},{"key":"2025122016065355700_R21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpba.2018.10.005","article-title":"UPLC-MS\/MS determination of suvorexant in urine by a simplified dispersive liquid-liquid micro-extraction followed by ultrasound assisted back extraction from solidified floating organic droplets","volume":"164","author":"Iqbal","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"2025122016065355700_R22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/jat\/bkw132","article-title":"Identification of suvorexant in urine using liquid chromatography-quadrupole\/time-of-flight mass spectrometry (LC-Q\/TOF-MS)","volume":"41","author":"Sullinger","year":"2017","journal-title":"J Anal Toxicol"},{"key":"2025122016065355700_R23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jchromb.2018.05.006","article-title":"Quantification of suvorexant in blood using liquid chromatography-quadrupole\/time of flight (LC-Q\/TOF) mass spectrometry","volume":"1091","author":"Skillman","year":"2018","journal-title":"J Chromatogr B"},{"key":"2025122016065355700_R24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jat\/bkz083","article-title":"Identification of suvorexant in blood using LC\u2013MS-MS: important considerations for matrix effects and quantitative interferences in targeted assays","volume":"44","author":"Skillman","year":"2020","journal-title":"J Anal Toxicol"},{"key":"2025122016065355700_R25","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-024-00700-5","article-title":"Incorporation of suvorexant and lemborexant into hair and their distributions after a single intake","volume":"43","author":"Nitta","year":"2024","journal-title":"Forensic Toxicology"},{"key":"2025122016065355700_R26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113359","article-title":"Establishment of a simultaneous assay for lemborexant, a novel dual orexin receptor antagonist, and its three metabolites, and its application to a clinical protein binding study","volume":"187","author":"Mano","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"2025122016065355700_R27","doi-asserted-by":"crossref","article-title":"Quantification of Daridorexant in Human Plasma Using RPHPLC: A Bioanalytical Method Development and Validation","author":"Pavani","DOI":"10.1039\/9781837671090-00211"},{"key":"2025122016065355700_R28","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1111\/cts.13079","article-title":"Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment","volume":"14","author":"Berger","year":"2021","journal-title":"Clin Transl Sci"},{"key":"2025122016065355700_R29","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2020.110307","article-title":"CYP450-Mediated metabolism of suvorexant and investigation of metabolites in forensic case specimens","volume":"312","author":"Skillman","year":"2020","journal-title":"Forensic Sci Int"},{"key":"2025122016065355700_R30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/jat\/bkx110","article-title":"Tissue Distribution of Suvorexant in Three Forensic Autopsy Cases","volume":"42","author":"Waters","year":"2018","journal-title":"J Anal Toxicol"},{"key":"2025122016065355700_R31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/00498254.2023.2183159","article-title":"The metabolism of the dual orexin receptor antagonist daridorexant","volume":"53","author":"Treiber","year":"2023","journal-title":"Xenobiotica"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkaf032\/62996003\/bkaf032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/49\/7\/469\/62996003\/bkaf032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/49\/7\/469\/62996003\/bkaf032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T21:07:10Z","timestamp":1766264830000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/49\/7\/469\/8118879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4,23]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkaf032","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,4,23]]}}}